Lung cancer treatment with or without artery chemotherapy
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding a special chemotherapy procedure (bronchial artery chemoembolization) to standard treatment improves outcomes for advanced lung squamous cell carcinoma patients who have already completed initial chemotherapy and immunotherapy. The procedure delivers cancer-fighting drugs directly to blood vessels feeding the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of squamous cell carcinoma (a type of lung cancer) at stage IV (most advanced)
- Completed 4–6 cycles of standard chemotherapy plus immunotherapy with good response (partial shrinkage or stable disease)
- Age 18–80 years old
- Good overall health status (ECOG score 0–1, meaning you can do most normal activities)
- Normal or near-normal blood counts, liver function, and kidney function
- Expected to live at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called bronchial artery chemoembolization (BACE) combined with drug therapy for advanced non-small cell lung cancer. BACE delivers chemotherapy directly to the tumor through the blood vessel that feeds it, which may help control the cancer when standard treatments have stopped working.
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy and a type of high-dose radiation therapy called Quad Shot for people with advanced lung cancer that has no known gene mutations. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests whether giving a combination of two targeted drugs (tislelizumab and anlotinib) plus standard chemotherapy before and after surgery can help people with early-stage lung cancer. The goal is to see if this approach can shrink the tumor and lower the chance of the cancer coming back.
This trial combines surgery to remove the main lung tumor with chemo and an immunotherapy drug called sintilimab. It's for people with advanced non-small cell lung cancer that hasn't been treated before and doesn't have certain gene changes.
This trial is for people with advanced non-small cell lung cancer whose tumors responded well to initial chemo-immunotherapy. Instead of giving full chest radiation, doctors will only target the main tumor to see if it can prevent regrowth with fewer side effects.
This trial is testing a combination of immunotherapy and targeted radiation for people with advanced lung cancer that has no targetable gene changes. The goal is to see if adjusting radiation based on how well the tumor responds can improve outcomes.
Hear when a new Lung Squamous Cell Carcinoma Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.